SALMAN ABDUL WAHEED
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology JOLIET, IL NPI 1104146505
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology IL Avyxa Pharma, LLC All categories
General Payments — all program years on this page
$6,320.92
- Category: General Payments
- Program years: PY2018–2024
- Record count: 258
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,543.22 across 49 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,543.22 | 49 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Avyxa Pharma, LLC | $423.53 | 1 |
| Daiichi Sankyo Inc. | $125.71 | 5 |
| E.R. Squibb & Sons, L.L.C. | $103.76 | 4 |
| ABBVIE INC. | $92.31 | 5 |
| Genentech USA, Inc. | $87.28 | 4 |
| Merck Sharp & Dohme Corporation | $82.57 | 3 |
| Janssen Biotech, Inc. | $62.14 | 3 |
| Tempus AI, Inc | $60.68 | 3 |
| PFIZER INC. | $51.65 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $45.64 | 2 |
| Alexion Pharmaceuticals, Inc. | $44.32 | 2 |
| Acerta Pharma LLC | $42.07 | 2 |
| Inari Medical, Inc. | $36.49 | 1 |
| GENZYME CORPORATION | $30.72 | 1 |
| Regeneron Healthcare Solutions, Inc. | $28.57 | 1 |
| Stemline Therapeutics Inc. | $28.10 | 1 |
| Lilly USA, LLC | $26.06 | 1 |
| Myriad Genetic Laboratories, Inc. | $25.00 | 1 |
| Celgene Corporation | $23.52 | 1 |
| Incyte Corporation | $23.42 | 1 |
| Mirati Therapeutics, Inc. | $22.92 | 1 |
| Gilead Sciences, Inc. | $21.59 | 1 |
| Invivyd Inc | $19.10 | 1 |
| EMD Serono, Inc. | $18.46 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $17.61 | 1 |
By program year
Records — PY2024 (49)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.